Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

myeloid leukemia cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	BMI1 (1) ADC Antibody (2) Akt (22) AMPK (2) Anaplastic lymphoma kinase (ALK) (2) Antibiotic (4) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (150) Arenavirus (1) Atg8/LC3 (4) Aurora Kinase (2) Autophagy (8) Bacterial (4) Bcl-2 Family (25) Bcr-Abl (15) Biochemical Assay Reagents (2) Btk (2) c-Fms (1) c-Kit (6) c-Met/HGFR (1) c-Myc (9) Casein Kinase (3) Caspase (14) CD3 (2) CDK (10) Ceramidase (1) Checkpoint Kinase (Chk) (2) ClpP (1) CRM1 (1) Cuproptosis (1) CXCR (2) Deubiquitinase (1) DGK (2) Dihydroorotate Dehydrogenase (1) Discoidin Domain Receptor (1) DNA Methyltransferase (4) DNA/RNA Synthesis (7) Drug Intermediate (1) Drug Isomer (1) E1/E2/E3 Enzyme (4) Endogenous Metabolite (16) Epigenetic Reader Domain (16) ERK (6) Estrogen Receptor/ERR (1) Eukaryotic Initiation Factor (eIF) (1) FAK (1) Farnesyl Transferase (1) Fat Mass and Obesity-associated Protein (FTO) (4) Ferroptosis (3) FGFR (1) FLT3 (51) Fungal (3) G protein-coupled Bile Acid Receptor 1 (1) G2A (GPR132) (1) GSK-3 (1) HDAC (19) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (10) Histone Acetyltransferase (3) Histone Demethylase (11) Histone Methyltransferase (5) HIV (1) HSP (5) IKZF Family (2) IMPDH (1) Interleukin Related (5) IRAK (1) Isocitrate Dehydrogenase (IDH) (5) Isotope-Labeled Compounds (8) JAK (10) KLF (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (2) LPL Receptor (1) MARK (2) MDM-2/p53 (7) MEK (1) METTL3 (1) Microtubule/Tubulin (2) Mitochondrial Metabolism (2) MMP (2) MNK (2) Molecular Glues (7) Monoamine Oxidase (1) mTOR (1) NF-κB (4) P-glycoprotein (2) p38 MAPK (16) p62 (3) p97 (2) PACAP Receptor (2) Parasite (2) PARP (5) PDGFR (2) PERK (2) Phosphatase (1) PI3K (8) Pim (5) PIN1 (1) Polo-like Kinase (PLK) (1) Prion Protein (2) PROTACs (27) Pyroptosis (1) Raf (1) RANKL/RANK (1) RAR/RXR (1) Ras (3) Reactive Oxygen Species (ROS) (17) Reference Standards (6) RET (2) ROS Kinase (1) RUNX (1) Salt-inducible Kinase (SIK) (2) Scavenger Receptor Class B type I (SR-BI） (1) SF3B1 (1) SHP2 (1) Small Interfering RNA (siRNA) (1) SphK (1) Src (2) STAT (21) TAM Receptor (1) Topoisomerase (3) Transferrin Receptor (1) Transmembrane Glycoprotein (4) Trk Receptor (1) VEGFR (2) WDR5 (1) Wee1 (1) Wnt (1) YTHDF (1) β-catenin (2)
By Research Areas:	Cancer (289) Cardiovascular Disease (6) Endocrinology (11) Infection (12) Inflammation/Immunology (34) Metabolic Disease (3) Neurological Disease (16)
Click Chemistry:	PROTAC Synthesis (1)

299

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: TREM receptor Nuclear Factor of activated T Cells (NFAT) BMI1 Programmed Cell Death 4 (PDCD4)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99014

Cusatuzumab 1 Publications Verification ARGX-110	Apoptosis	Inflammation/Immunology Cancer
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .

HY-158341

IOX5	HIF/HIF Prolyl-Hydroxylase Apoptosis	Cancer
IOX5 is a selective prolyl hydroxylase (PHD) inhibitor with an IC₅₀ of 0.19 μM for PHD2. IOX5 stabilizes HIF-1α in acute myeloid leukemia (AML) cells, inhibits cell proliferation and induces apoptosis. IOX5 has anti-leukemia activity .

HY-129592

p-Tolylmaleimide	Apoptosis	Cancer
p-Tolylmaleimide (compound 9) is a naphthalimide derivative that has cytotoxic effects on cancer cells. p-Tolylmaleimide can arrest the cell cycle of human acute myeloid leukemia cells K562 in the sub-G0/G1 phase and induce apoptosis .

HY-112218

MIK665 15+ Cited Publications S-64315	Bcl-2 Family	Cancer
MIK665 (S-64315), derived from S63845, is a myeloid cell leukemia sequence 1 (MCL1) inhibitor . MIK665 has an IC₅₀ of 1.81 nM for MCL1 .

HY-142690A

HDAC-IN-27 dihydrochloride	Apoptosis HDAC	Cancer
HDAC-IN-27 dihydrochloride (Compound 11h) is a potent, orally active class I HDAC-selective inhibitor with IC₅₀ values ranging from 0.43 to 3.01 nM against HDAC1-3. HDAC-IN-27 dihydrochloride exhibits both in vivo and in vitro antitumor activity. HDAC-IN-27 dihydrochloride demonstrates significant anti-proliferative activity against acute myeloid leukemia (AML) cell lines by inducing apoptosis and histone acetylation (AcHH3 and AcHH4). HDAC-IN-27 dihydrochloride can be used for research in acute myeloid leukemia (AML) .

HY-162489

Tyrosine kinase-IN-8	Bcr-Abl	Others
Tyrosine kinase-IN-8 (compound 4e) is a BCR‐ABL1 tyrosine kinase inhibitor (TKI). Tyrosine kinase-IN-8 shows anti-proliferative activity against K562 cells, a chronic myeloid leukemia (CML) cell line (CC₅₀=0.8 µM). Tyrosine kinase-IN-8 can be used in the study of chronic leukemia .

HY-173481

CDK9-IN-37	CDK	Cancer
CDK9-IN-37 (Compound 24) is a CDK9 inhibitor (EC₅₀: 5.5 nM) with weak inhibition on other CDK isoforms, showing high selectivity. CDK9-IN-37 has significant antiproliferative activity against acute myeloid leukemia MOLM-13 cells (IC₅₀: 0.034 μM). CDK9-IN-37 inhibits the CDK9 signaling pathway, reduces the phosphorylation level of RNAP II CTD (Ser2), downregulates the anti-apoptotic protein McI-1, induces cell apoptosis, and arrests the cell cycle at the G2/M phase. CDK9-IN-37 can be used in the study of acute myeloid leukemia (AML) .

HY-162906

FLT3/HDAC-IN-2	HDAC FLT3	Cancer
FLT3/HDAC-IN-2 is (compound 25h) a FLT3/HDAC dual inhibitor. FLT3/HDAC-IN-2 has antiproliferative activity against MOLM-13 cells. FLT3/HDAC-IN-2 can be used in acute myeloid leukemia research .

HY-168605

DH-18	MMP Apoptosis	Cancer
DH-18 is a matrix metalloproteinase-2 (MMP-2) inhibitor with the IC₅₀ values of 139.45 nM, 518.11 nM and 833.34 nM for MMP-2, MMP-9 and MMP-8, respectively. DH-18 induces cell apoptosis and arrests cell cycle in the G0/G1 phase. DH-18 inhibits cell growth and can be used for study of chronic myeloid leukemia .

HY-142690

HDAC-IN-27	HDAC Apoptosis	Cancer
HDAC-IN-27 (Compound 11h) is a potent, orally active class I HDAC-selective inhibitor with IC₅₀ values ranging from 0.43 to 3.01 nM against HDAC1-3. HDAC-IN-27 exhibits both in vivo and in vitro antitumor activity. HDAC-IN-27 demonstrates significant anti-proliferative activity against acute myeloid leukemia (AML) cell lines by inducing apoptosis and histone acetylation (AcHH3 and AcHH4). HDAC-IN-27 can be used for research in acute myeloid leukemia (AML) .

HY-126920

AFG206	FLT3 Apoptosis	Cancer
AFG206 is a first-generation ATP competitive “type II” FLT3 inhibitor. AFG206 potently inhibits cell proliferation (IC₅₀ around 0.1 µM) via induction of Apoptosis in FLT3-ITD-Ba/F3 cells and D835Y-Ba/F3 cells. AFG206 is promising for research of acute myeloid leukemia .

HY-16271

Kevetrin hydrochloride 4 Publications Verification 4-Isothioureidobutyronitrile hydrochloride; thioureidobutyronitrile hydrochloride; thioureido butyronitrile hydrochloride	MDM-2/p53 Apoptosis	Cancer
Kevetrin hydrochloride is a potent activator of p53, induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. Kevetrin a preferential cytotoxic activity against blast cells .

HY-178010

Mcl-1-IN-17	Bcl-2 Family Apoptosis	Cancer
Mcl-1-IN-17 (Compound 25) is an orally active Myeloid Cell Leukemia 1 (Mcl-1) inhibitor with a K_i < 0.08  nM. Mcl-1-IN-17 has a significant antiproliferative activity (GI₅₀s of 39 and 105  nM for H929 and A427 cells, respectively) and inhibits cell apoptosis. Mcl-1-IN-17 can be used for hematological and solid cancers research .

HY-144782

HDAC10-IN-2	HDAC Autophagy	Cancer
HDAC10-IN-2 (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 20 nM. HDAC10-IN-2 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-144782A

HDAC10-IN-2 hydrochloride	HDAC Autophagy	Cancer
HDAC10-IN-2 hydrochloride (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 20 nM. HDAC10-IN-2 hydrochloride modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-144779

HDAC10-IN-1	HDAC Autophagy	Cancer
HDAC10-IN-1 (compound 13b) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 58 nM. HDAC10-IN-1 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-128888B

(S,R)-GSK321	Isocitrate Dehydrogenase (IDH)	Cancer
(S,R)-GSK321 is the (S,R)-enantiomer of GSK321 (HY-18948). GSK321 is a potent, selective mutant IDH1 inhibitor with IC₅₀ values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .

HY-N12641

Ardisianone	Apoptosis Pyroptosis	Cancer
Ardisianone is a component with an alkyl benzoquinone structure that can be isolated from Ardisia virens Kurz and Ardisia compressa tea extract. Ardisianone exhibits potent antileukemic activity, particularly against HL-60 cells, with IC₅₀ values of 1.87 μM (24 h) and 1.67 μM (48 h). Ardisianone induces caspase-dependent apoptosis and triggers pyroptosis. Ardisianone can be used for the study of acute myeloid leukemia (AML) .

HY-175783

MM927	Apoptosis	Cancer
MM927 is a potent NVL inhibitor, with an IC₅₀ of 0.053 μM. MM927 blocks 60S ribosomal subunit biogenesis in the nucleolus. MM927 induces half-mer polysomes, cell cycle arrest at G1/S and G2/M and apoptosis in cells. MM927 demonstrates antitumor efficacy in MOLM-13 AML and HCT116 CRC xenograft models. MM927 can be used for the study of cancers such as acute myeloid leukemia (AML) and colorectal cancer (CRC) .

HY-12892

SKI-178 1 Publications Verification	SphK Apoptosis	Cancer
SKI-178 is a potent sphingosine kinase-1 (SphK1) and SphK2 inhibitor. SKI-178 is cytotoxic at IC₅₀ concentrations ranging from 1.8 to 0.1 μM in both agent sensitive and multi-agent resistant cancer cell lines (i.e., MTR3, NCI-ADR and HL60/VCR cells). SKI-178 induces apoptosis in a CDK1-dependent manner in human acute myeloid leukemia cell lines .

HY-178500

WCY-8-67	Deubiquitinase Apoptosis STAT JAK Akt PI3K	Cancer
WCY-8-67 is an orally active and selective USP5 inhibitor, with an IC₅₀ value of 1.33 μM. WCY-8-67 induces apoptosis and suppresses JAK/STAT3 and PI3K/AKT signaling pathways in vitro. WCY-8-67 inhibits proliferation of AE-positive AML cells, induces G1 phase arrest and differentiation of AML cells. WCY-8-67 demonstrates potent anti-leukemic efficacy in mice. WCY-8-67 can be used for the study of acute myeloid leukemia .

HY-174911

FLT3-IN-33	FLT3 Apoptosis	Cancer
FLT3-IN-33 (Compound 7r) is a FLT3 inhibitor with an IC₅₀ of 7.82  nM. FLT3-IN-33 has superior anticancer activities against acute myeloid leukemia (AML) cells, such as MV4-11 and MOLM-13 cells. FLT3-IN-33 significantly induces cell apoptosis and inhibits phosphorylation of FLT3 pathways. FLT3-IN-33 can be used for AML and other cancers research .

HY-162936

SILA-123	FLT3 Apoptosis	Cancer
SILA-123 is a FLT3 inhibitor (FLT3-WT: IC₅₀=2.1 nM; FLT3-ITD: IC₅₀=1.0 nM). SILA-123 inhibits FLT3 phosphorylation and downstream signaling pathways, leading to apoptosis by arresting cell cycle progression at the G0/G1 phase. SILA-123 can be used in the study of acute myeloid leukemia .

HY-144675A

LSD1-IN-13 hydrochloride	Histone Demethylase	Cancer
LSD1-IN-13 hydrochloride (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 hydrochloride can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 hydrochloride induces differentiation of AML (acute myeloid leukemia) cell lines .

HY-144675

LSD1-IN-13	Histone Demethylase	Cancer
LSD1-IN-13 (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 induces differentiation of AML (acute myeloid leukemia) cell lines .

HY-115906

K783-0308	FLT3 MNK Apoptosis	Cancer
K783-0308 is a potent and selective dual inhibitor of FLT3 and MNK2 with IC₅₀ values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC₅₀=10.5 µM) and MV-4-11 (IC₅₀=10.4 µM) cells. K783-0308 promotes acute myeloid leukemia (AML) cell apoptosis and cell cycle arrests in the G0/G1 phase .

HY-174979

Dac590	Fat Mass and Obesity-associated Protein (FTO) Apoptosis	Cancer
Dac590 is an orally active FTO inhibitor. Dac590 has a robust antiproliferative effect on AML cells, and induces apoptosis and cell cycle G1 arrest by inhibiting oncogenic FTO signaling. Dac590 significantly inhibits tumor growth and prolongs survival with no observed toxicity in acute myeloid leukemia (AML) xenograft mcie model, and shows a synergistic effect combined with Decitabine (HY-A0004) .

HY-123486

HS-438	Apoptosis Bcr-Abl	Cancer
HS-438 is a potent and selective BCR-ABL inhibitor. HS-438 shows antiproliferative activity. HS-438 decreases the expression of phosphorylation of BCR-ABL (Tyr177). HS-438 induces apoptosis and cell cycle arrest at G0/G1 phase. HS-438 shows antitumor activity. HS-438 has the potential for the research of chronic myeloid leukemia (CML) .

HY-12083

PPY-A	Bcr-Abl	Cancer
PPY-A is a potent T315I mutant and wild-type Abl kinases inhibitor with IC₅₀s of 9 and 20 nM, respectively. PPY-A inhibits Ba?F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC₅₀s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML) .

HY-142696

CDK6/PIM1-IN-1	CDK Pim Apoptosis	Cancer
CDK6/PIM1-IN-1 is a potent and balanced dual CDK6/PIM1 inhibitor with IC₅₀ values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 inhibits CDK4 (IC₅₀=3.6 nM). CDK6/PIM1-IN-1 significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity .

HY-142696A

CDK6/PIM1-IN-1 hydrochloride	CDK Pim Apoptosis	Cancer
CDK6/PIM1-IN-1 (Compound 51) hydrochloride is an orally active and potent dual CDK6/PIM1 inhibitor with IC₅₀ values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 hydrochloride inhibits CDK4 (IC₅₀=3.6 nM). CDK6/PIM1-IN-1 hydrochloride significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity .

HY-164542

TQ05310	Isocitrate Dehydrogenase (IDH)	Cancer
TQ05310 is an orally available inhibitor of IDH2 mutants, targeting both IDH2-R140Q (IC₅₀=136.9 nM) and IDH2-R172K (IC₅₀=37.9 nM) mutants. TQ05310 inhibits the production of 2-hydroxyglutarate (2-HG) and induces differentiation of cells expressing IDH2-R140Q and IDH2-R172K by inhibiting the enzymatic activity of mutant IDH2. TQ05310 can be used for the study of acute myeloid leukemia .

HY-128607

Mcl1-IN-9	Bcl-2 Family	Cancer
Mcl1-IN-9 is a potent myeloid cell leukemia-1 (Mcl-1) Inhibitor with an IC₅₀ of 446 nM in reengineered BCR-ABL+ B-ALL cells and a K_i of 0.03 nM .

HY-146749

FLT3/TrKA-IN-1	FLT3 Trk Receptor Apoptosis	Cancer
FLT3/TrKA-IN-1 is a potent FLT3/TrKA dual kinase inhibitor with the IC₅₀s of 43.8 nM, 97.2 nM, 92.5 nM and 23.6 nM for FLT3, FLT3-ITD, FLT3-TKD and TrKA, respectively. FLT3/TrKA-IN-1 induces cell cycle arrest at the G0/G1 phase as well as apoptosis and shows antiproliferative activity in vitro. FLT3/TrKA-IN-1 has the potential for the research of Acute myeloid leukemia (AML) .

HY-139877

OXS007417	Microtubule/Tubulin	Cancer
OXS007417 induces differentiation of acute myeloid leukemia cells (EC₅₀ = 48 nM) in vitro and shows antitumor effects in vivo.

HY-148422

Rohinitib 1 Publications Verification	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML .

HY-178858

PROTAC FLT3/CHK1 Degrader-1	PROTACs FLT3 Checkpoint Kinase (Chk) STAT ERK c-Myc Akt	Cancer
PROTAC FLT3/CHK1 Degrader-1 is a PROTAC FLT3/CHK1 degrader, with DC₅₀ values of 5.88 nM (FLT3) and 4.17 nM (CHK1), respectively. PROTAC FLT3/CHK1 Degrader-1 can inhibit the phosphorylation of FLT3 downstream signaling effectors STAT5 (Tyr694), AKT (Ser473), and ERK (Tyr204), downregulate the protein level of c-Myc and maintain the expression of p53 protein. PROTAC FLT3/CHK1 Degrader-1 induces apoptosis in MV-4-11 cells. PROTAC FLT3/CHK1 Degrader-1 shows significant anti-tumor efficacy in mice bearing MV-4-11 subcutaneous xenografts. PROTAC FLT3/CHK1 Degrader-1 can be used for the study of acute myeloid leukemia (AML). (Pink: FLT3/CHK1 ligand (HY-178869 ), Blue: CRBN Ligand (HY-W093272), Black: Linker, E3 ligase ligand-linker conjugate (HY-W998238)) .

HY-171146

HSN748	FLT3 Bcr-Abl RET PDGFR MNK	Cancer
HSN748 is a Ponatinib (HY-12047) analogue and a multikinase inhibitor. HSN748 has inhibitory activity on FLT3, ABL1, RET, PDGFRα/β, MNK1, MNK2 and other kinases. HSN748 can inhibit the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines and can be used in the study of leukemia .

HY-168475

DD0-2363	Apoptosis WDR5 HDAC	Cancer
DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. DD0-2363 inhibits cells proliferation and induces apoptosis in acute myeloid leukemia cells. DD0-2363 has antitumor activity and can be used in the research of acute myeloid leukemia .

HY-154961

Mcl-1 inhibitor 14	Bcl-2 Family	Cancer
Mcl-1 inhibitor 14 (Compound (Ra)-10) is an inhibitor of myeloid cell leukemia-1 (MCL-1) with an K_i of 0.018 nM and can be used for anticancer research .

HY-155361

PROTAC BRD9 Degrader-7	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD9 Degrader-7 is an orally active, selective BRD9 PROTAC degrader (DC₅₀ = 1.02 nM). PROTAC BRD9 Degrader-7 mediates BRD9 degradation via the ubiquitin-proteasome system. PROTAC BRD9 Degrader-7 exhibits proliferation inhibitory activity in the MV4-11 cells. PROTAC BRD9 Degrader-7 can be used in the research of acute myeloid leukemia and other related malignancies. (Pink: BI 7271: HY-123616, Blue: 5-Aminothalidomide: HY-W023573, Blue + Black: Thalidomide-5-piperazine: HY-W834174, Black: N,N'-Dimethylpiperazine: HY-W539783) .

HY-100741

S63845 Maximum Cited Publications 96 Publications Verification	Bcl-2 Family	Cancer
S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor with a K_d of 0.19 nM for human MCL1 .

HY-150507

JNJ-4355 JNJ-78394355	Bcl-2 Family	Cancer
JNJ-4355, a chemical probe, is a highly potent MCL-1 (myeloid cell leukemia-1) inhibitor, with K_I of 18 pM. JNJ-4355 shows antitumor activity .

HY-125908

A-1210477-piperazinyl PROTAC Mcl1-binding moiety 1	Ligands for Target Protein for PROTAC	Cancer
A-1210477-piperazinyl is a compound binds to protein myeloid cell leukemia 1 (MCL1) used for PROTAC technology .

HY-110071

APcK110	c-Kit	Cancer
APcK110 is a potent Kit inhibitor that can be used for the research of acute myeloid leukemia (AML). APcK110 induces AML cell apoptosis .

HY-175164

SVC112	Apoptosis c-Myc	Cancer
SVC112 is a translation elongation inhibitor that prevents the cyclic dissociation of EF2 from the ribosome, thereby inhibiting the elongation step of translation. SVC112 shows activity in growth inhibition among cancer cell lines of various origins (acute myeloid leukemia (AML), multiple myeloma (Myeloma), colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC)). SVC112 preferentially impedes ribosomal processing of mRNAs, and decreaseds CSC-related proteins including Myc and Sox2. SVC112 induces apoptosis in hematologic cancer cell lines, while phosphorylation of c-Myc correlates with sensitivity to SVC112 in colorectal cancer cell lines. SVC112 inactivates HNSCC stem cells in vitro and prevents the regrowth of HNSCC tumor xenografts in mice. SVC112 can be used for the study of HNSCC .

HY-163293

Mcl-1 inhibitor 18	Bcl-2 Family	Cancer
Mcl-1 inhibitor 18 (compound 57) is a myeloid cell leukemia 1 (Mcl-1) inhibitor, and can be used for study of cancer .

HY-136175

Revumenib 10+ Cited Publications SNDX-5613	Epigenetic Reader Domain	Cancer
Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding K_i of 0.149 nM and a cell based IC₅₀ of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .

HY-175610

PROTAC FLT3/JAK2/BRD4 Degrader-1	PROTACs FLT3 JAK Epigenetic Reader Domain	Cancer
PROTAC FLT3/JAK2/BRD4 Degrader-1 is a PROTAC degrader that target FLT3, JAK2, and BRD4 with DC₅₀ values of 5.23, 0.678, and 1.17 nM, respectively. PROTAC FLT3/JAK2/BRD4 Degrader-1 exhibits potent antiproliferative activity against MV4;11 cells (IC₅₀ = 0.79 nM) and FLT3 mutant-transformed Ba/F3 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 induces apoptosis in MV4;11 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 demonstrates significant anti-tumor efficacy in the MV4;11 xenograft model established in NOD SCID mice. PROTAC FLT3/JAK2/BRD4 Degrader-1 can be used for the study of acute myeloid leukemia (AML). (Pink: FLT3/JAK2/BRD4 ligand (HY-175611), Blue: CRBN Ligand (HY-W087383), Black: Linker, E3 ligase ligand-linker conjugate (HY-W897939)) .

HY-177467

P0064	Others	Cancer
P0064 is a selective inhibitor targeting the PR domain of PRDM16. P0064 selectively reduces proliferation and survival of FLT3-ITD+ leukemia cells. P0064 is promising for research of acute myeloid leukemia (AML) .

Cat. No.	Product Name	Type

HY-Y1103A

Iron(II) sulfate heptahydrate, for cell culture, 99%

Ferrous sulfate heptahydrate, for cell culture, 99%

Buffer Reagents

Iron(II) sulfate heptahydrate, for cell culture, 99% (Ferrous sulfate heptahydrate, for cell culture, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, for cell culture, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, for cell culture, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, for cell culture, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer .

HY-10475G

AM580 (GMP) CD336 (GMP); NSC608001 (GMP); Ro 40-6055 (GMP)	Biochemical Assay Reagents
AM580 (CD336) (GMP) is AM580= (HY-10475) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AM580 is a selective RARα agonist .

Cat. No.	Product Name	Target	Research Area

HY-P3508A

PNC-27 acetate	MDM-2/p53	Cancer
PNC-27 acetate, a chimeric p53-penetratin peptide binds to HDM-2 in a p53 peptide-like structure, induces selective membrane-pore formation and leads to cancer cell lysis. PNC-27 acetate is an anticancer peptide. PNC-27 acetate can be used in acute myeloid leukemia research .

HY-P3508

PNC-27	MDM-2/p53	Cancer
PNC-27, a chimeric p53-penetratin peptide binds to HDM-2 in a p53 peptide-like structure, induces selective membrane-pore formation and leads to cancer cell lysis. PNC-27 is an anticancer peptide. PNC-27 can be used in acute myeloid leukemia research .

HY-P11288A

ANT308 TFA	PACAP Receptor Apoptosis	Cancer
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

HY-P11288

ANT308	PACAP Receptor Apoptosis	Cancer
ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

Cat. No.	Product Name	Target	Research Area

HY-P99014

Cusatuzumab 1 Publications Verification ARGX-110	Apoptosis	Inflammation/Immunology Cancer
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .

HY-P99971

Gemtuzumab	ADC Antibody Transmembrane Glycoprotein	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P99521

Vibecotamab XmAb14045	CD3	Inflammation/Immunology Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and CD3. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .

HY-P990002

Anti-Mouse CD117/c-Kit Antibody (2B8)	c-Kit	Inflammation/Immunology Cancer
Anti-Mouse CD117/c-Kit Antibody (2B8) is an IgG2b antibody, targeting to mouse CD117/c-Kit. Anti-Mouse CD117/c-Kit Antibody (2B8) reacts with mouse c-Kit (also known as CD117), which is expressed on hematopoietic progenitor cells, mast cells, and acute myeloid leukemia (AML) cells. Anti-Mouse CD117/c-Kit Antibody (2B8) can be used for the detection of flow cytometry, immunofluorescence and immunohistochemistry in cancer and inflammation .

HY-P991425

AT-1413	Transmembrane Glycoprotein	Cancer
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991648

CSL-360	Interleukin Related	Cancer
CSL-360 is a chimeric unconjugated IgG1 monoclonal antibody targeting CD123. CSL-360 efficiently prevents the binding of IL-3 to CD123, abolishing IL-3 induced cell proliferation. CSL-360 can be used for acute myeloid leukemia (AML) research .

HY-P991665

MEN1112 OBT357NF; OBT357	Transmembrane Glycoprotein	Cancer
MEN1112 (OBT357NF) is a selective humanized monoclonal antibody targeting the Bst1/CD157 antigen (EC₅₀=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML .

HY-P991656

LY-2624587	CXCR Apoptosis p38 MAPK Akt	Cancer
LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .

HY-P991669

IGN523	Caspase Apoptosis	Cancer
IGN523 is an anti-CD98 antibody (hCD98, K_D = 0.55 nM). IGN523 induces antibody-dependent cell-mediated cytotoxicity (ADCC) activity, lysosomal membrane permeabilization, and inhibition of essential amino acid transport, ultimately leading to caspase-3 and caspase-7-mediated apoptosis of tumor cells. IGN523 inhibits tumor growth in multiple tumor xenograft models. IGN523 is useful in the research of non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), and other cancers. .

HY-P991294

MGTA-117 Antibody	ADC Antibody	Cancer
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .

HY-P99395

Talacotuzumab 1 Publications Verification JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

HY-P99488

Briquilimab JSP-191; AMG-191	c-Kit	Inflammation/Immunology Cancer
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13680

Meisoindigo 1 Publications Verification Dian III; N-Methylisoindigotin; Natura-α	Alkaloids other families Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Cancer	Apoptosis
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity .

HY-N0071

Crotonoside Isoguanosine	Alkaloids Classification of Application Fields Other Alkaloids Croton tiglium Linn. Source classification Euphorbiaceae Plants Disease Research Fields Cancer	FLT3 HDAC
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML .

HY-13653

(-)-Epigallocatechin Gallate Maximum Cited Publications 48 Publications Verification EGCG; Epigallocatechol Gallate	Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Flavonoids other families Flavonones Phenols Polyphenols Inflammation/Immunology Disease Research Fields Cancer	Endogenous Metabolite Apoptosis
(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-N12641

Ardisianone	Quinones Source classification Benzene Quinones Plants Primulaceae	Apoptosis Pyroptosis
Ardisianone is a component with an alkyl benzoquinone structure that can be isolated from Ardisia virens Kurz and Ardisia compressa tea extract. Ardisianone exhibits potent antileukemic activity, particularly against HL-60 cells, with IC₅₀ values of 1.87 μM (24 h) and 1.67 μM (48 h). Ardisianone induces caspase-dependent apoptosis and triggers pyroptosis. Ardisianone can be used for the study of acute myeloid leukemia (AML) .

HY-N15653

Heveadride	Natural Products Microorganisms Source classification	Endogenous Metabolite Fungal NF-κB
Heveadride is a fungal metabolite and an antifungal agent. Heveadride is active against various filamentous fungi and some human pathogenic yeasts. Heaveadride induces down-regulation of TNFα-induced NF-κB activity in human chronic myeloid leukemia cells with an IC₅₀ of 82.7 μM .

HY-13680R

Meisoindigo (Standard)	Alkaloids other families Source classification Plants Indole Alkaloids	Apoptosis
Meisoindigo (Standard) is the analytical standard of Meisoindigo. This product is intended for research and analytical applications. Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity .

HY-N3210

Nb-Demethylechitamine	Apocynaceae Alkaloids Source classification Plants Indole Alkaloids Alstonia rostrata C. E. C. Fischer	Others
Nb-Demethylechitamine is an alkaloid isolated from the methanol extract of Alstonia rostrata twigs. Nb-Demethylechitamine has in vitro cytotoxic activity against several human cancer cell lines, including human myeloid leukemia HL-60, liver cancer SMMC-7721, lung cancer A-549, breast cancer MCF-7, and colon cancer SW480 cells .

HY-123121

Nargenicin A1	Infection Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Inflammation/Immunology Disease Research Fields Cancer	Antibiotic Apoptosis Bacterial NF-κB
Nargenicin A1 is an antibiotic agent against various Gram-positive bacteria. Nargenicin A1 shows anti-inflammatory activity. Nargenicin A1 protects HINAE cells against Tacrolimus (HY-13756)-induced DNA damage and apoptosis. Nargenicin A1 can also be used for the research of acute myeloid leukemia .

HY-B1899AR

Taurodeoxycholic acid sodium hydrate (Standard) Sodium taurodeoxycholate monohydrate (Standard)	Source classification Endogenous metabolite Steroids	Reference Standards G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite
(E)-Methyl 4-coumarate (Standard) is the analytical standard of (E)-Methyl 4-coumarate. This product is intended for research and analytical applications. (E)-Methyl 4-coumarate (Methyl 4-hydroxycinnamate), found in several plants, such as Allium cepa or Morinda citrifolia L. leaves. (E)-Methyl 4-coumarate cooperates with Carnosic Acid in inducing apoptosis and killing acute myeloid leukemia cells, but not normal peripheral blood mononuclear cells. Antioxidant and antimicrobial activity.

HY-150526

EGCG-4″-sulfate	Flavonoids Classification of Application Fields Flavanols Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Cancer	Endogenous Metabolite Apoptosis
EGCG-4″-sulfate is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate sulfate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. EGCG-4″-sulfate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-B0722

Histamine dihydrochloride 15+ Cited Publications	Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Histamine Receptor p38 MAPK Akt Reactive Oxygen Species (ROS) Apoptosis Endogenous Metabolite
Histamine dihydrochloride is the agonist for histamine receptor and a vasodilator. Histamine dihydrochloride is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine dihydrochloride affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine dihydrochloride can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-B1204

Histamine 15+ Cited Publications Ergamine	Natural Products Human Gut Microbiota Metabolites Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Cancer	Histamine Receptor p38 MAPK Akt Reactive Oxygen Species (ROS) Apoptosis Endogenous Metabolite
Histamine is the agonist for histamine receptor and a vasodilator. Histamine is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-A0129

Histamine phosphate 15+ Cited Publications Histamine diphosphate	Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Endocrinology Cancer	Histamine Receptor p38 MAPK Akt Reactive Oxygen Species (ROS) Apoptosis Endogenous Metabolite
Histamine phosphate is the agonist for histamine receptor and a vasodilator. Histamine phosphate is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine phosphate affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine phosphate can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-13653R

(-)-Epigallocatechin Gallate (Standard) Maximum Cited Publications 48 Publications Verification EGCG(Standard); Epigallocatechol Gallate (Standard)	Flavonoids other families Classification of Application Fields Anti-aging Source classification Phenols Plants Endogenous metabolite Inflammation/Immunology Disease Research Fields Cancer	Reference Standards Endogenous Metabolite Apoptosis
(-)-Epigallocatechin Gallate (Standard) is the analytical standard of (-)-Epigallocatechin Gallate. This product is intended for research and analytical applications. (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-N1746

(2S)-2'-Methoxykurarinone 2'-O-Methylkurarinone	Flavonoids Classification of Application Fields Leguminosae Flavonones Source classification Phenols Polyphenols Metabolic Disease Sophora flavescens Aiton Plants Inflammation/Immunology Disease Research Fields	RANKL/RANK
(2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells .

HY-121245

Capoamycin	Microorganisms Antibiotics Source classification	Antibiotic Bacterial Fungal
Capoamycin is an antibiotic. Capoamycin shows antimicrobial and antitumor activity .

HY-A0129R

Histamine phosphate (Standard) Histamine diphosphate (Standard)	Alkaloids Other Alkaloids Source classification Endogenous metabolite	Reference Standards Histamine Receptor p38 MAPK Akt Reactive Oxygen Species (ROS) Apoptosis Endogenous Metabolite
Histamine phosphate (Standard) is the analytical standard of Histamine phosphate (HY-A0129). This product is intended for research and analytical applications. Histamine phosphate is the agonist for histamine receptor and a vasodilator. Histamine phosphate is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine phosphate affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine phosphate can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-B1204R

Histamine (Standard) Ergamine (Standard)	Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite	Reference Standards Histamine Receptor p38 MAPK Akt Reactive Oxygen Species (ROS) Apoptosis Endogenous Metabolite
Histamine (Standard) is the analytical standard of Histamine (HY-B1204). This product is intended for research and analytical applications. Histamine is the agonist for histamine receptor and a vasodilator. Histamine is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-B0722R

Histamine dihydrochloride (Standard)	Natural Products Source classification Endogenous metabolite	Reference Standards Histamine Receptor p38 MAPK Akt Reactive Oxygen Species (ROS) Apoptosis Endogenous Metabolite
Histamine dihydrochloride (Standard) is the analytical standard of Histamine dihydrochloride (HY-B0722). This product is intended for research and analytical applications. Histamine dihydrochloride is the agonist for histamine receptor and a vasodilator. Histamine dihydrochloride is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine dihydrochloride affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine dihydrochloride can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-W018324

5-Hydroxymethylcytosine 5hmC	Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
5-Hydroxymethylcytosine (5hmC) is an oxidized forms of 5-methylcytosine (5mC) in mammalian DNA. 5-Hydroxymethylcytosine is produced from 5mC in an enzymatic pathway involving three 5mC oxidases, Ten-eleven translocation (TET)1, TET2, and TET3. The conversion of 5mC into 5hmC can be the first step in a pathway leading towards DNA demethylation. 5-Hydroxymethylcytosine is associated with gene transcription and frequently used as a mark to investigate dynamic DNA methylation conversion during mammalian development. 5-Hydroxymethylcytosine can be used for the study of non-small cell lung cancer (NSCLC), neurodegenerative diseases (Alzheimer’s, Parkinson’s) and hematological malignancies (acute myeloid leukemia, myelodysplastic syndromes) .

HY-N0007A

Bisdemethoxycucurmin Curcumin III; Didemethoxycurcumin	Zingiber officinale Roscoe Classification of Application Fields Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Zingiberaceae	Ferroptosis P-glycoprotein DNA/RNA Synthesis
Bisdemethoxycucurmin (Curcumin III) is a curcuminoid compound and an inhibitor of P-glycoprotein and ferroptosis. Bisdemethoxycucurmin exhibits multiple activities such as anti-oxidation, anti-inflammation and anti-tumor. Bisdemethoxycucurmin can be used for the research of tumors and inflammatory diseases .

Cat. No.	Product Name	Chemical Structure

HY-13653S1

(-)-Epigallocatechin Gallate-d4

(-)-Epigallocatechin Gallate-d₄ (EGCG-d₄) is the deuterium labeled (-)-Epigallocatechin Gallate (HY-13653). (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-15728S

Radotinib-d6

Radotinib-d₆ is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .

HY-B1204S1

Histamine-d4

Histamine-d₄ (Ergamine-d₄) is deuterium labeled Histamine (HY-B1204). Histamine is the agonist for histamine receptor and a vasodilator. Histamine is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-B1204S3

Histamine-13C5

Histamine- ¹³C₅ is the ¹³C labeled Histamine (HY-B1204). Histamine is the agonist for histamine receptor and a vasodilator. Histamine is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-170017S

(−)-Epigallocatechin Gallate-d3/d4

(-)-Epigallocatechin Gallate-d₃/d₄ (EGCG-d₃/d₄) is the deuterium labeled (-)-Epigallocatechin Gallate (HY-13653). (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-B1204S4

Histamine-15N3

Histamine- ¹⁵N₃ is the ¹⁵N₃-labeled Histamine (HY-B1204). Histamine is the agonist for histamine receptor and a vasodilator. Histamine is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-B1204S2

Histamine-13C5, 15N3

Histamine- ¹³C₅, ¹⁵N₃ (Ergamine- ¹³C₅, ¹⁵N₃) is the ¹³C and ¹⁵N labeled isotope of Histamine (HY-B1204). Histamine is the agonist for histamine receptor and a vasodilator. Histamine is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-W018324S

5-Hydroxymethylcytosine-13C,d2

5-Hydroxymethylcytosine- ¹³C,d₂ is the ¹³C and deuterium labeled 5-Hydroxymethylcytosine (HY-W018324). 5-Hydroxymethylcytosine (5hmC) is an oxidized forms of 5-methylcytosine (5mC) in mammalian DNA. 5-Hydroxymethylcytosine is produced from 5mC in an enzymatic pathway involving three 5mC oxidases, Ten-eleven translocation (TET)1, TET2, and TET3. The conversion of 5mC into 5hmC can be the first step in a pathway leading towards DNA demethylation. 5-Hydroxymethylcytosine is associated with gene transcription and frequently used as a mark to investigate dynamic DNA methylation conversion during mammalian development. 5-Hydroxymethylcytosine can be used for the study of non-small cell lung cancer (NSCLC), neurodegenerative diseases (Alzheimer’s, Parkinson’s) and hematological malignancies (acute myeloid leukemia, myelodysplastic syndromes) .

Cat. No.	Product Name		Classification

HY-150251

SD-91 STAT3 degrader-2		PROTAC Synthesis
SD-91 (STAT3 degrader-2), a product of the hydrolysis of SD-36 (HY-129602), is a selective PROTAC-based STAT3 degrader with a K_i of 5.5 nM. SD-91 displays >300-fold selectivity over other STAT family protein members. SD-91 potently induces degradation of STAT3 protein in cells. SD-91 has anticancer effects, such as myeloid leukemia, lymphoma (Pink: ligand for target protein (HY-150895); Black: linker; Blue: E3 ligase ligand; E3 ligase ligand+linker: HY-176506) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks